Products Categories
| CAS No.: | 7775-11-3 |
|---|---|
| Name: | Sodium chromate |
| Molecular Structure: | |
|
|
|
| Formula: | CrH2O4.2Na |
| Molecular Weight: | 163.97 |
| Synonyms: | Chromicacid (H2CrO4), disodium salt (8CI,9CI);Chromium disodium oxide;Chromiumsodium oxide (CrNa2O4);Disodium chromate;Disodium chromate (Na2CrO4);Sodiumchromate;Sodium chromate (Na2(CrO4));Sodium chromate (VI);Sodium chromiumoxide (Na2CrO4); |
| EINECS: | 231-889-5 |
| Density: | 2.72 g/cm3 |
| Melting Point: | 792 °C |
| Boiling Point: | 392oC |
| Solubility: | soluble in water |
| Appearance: | Yellow crystals or crystalline powder |
| Hazard Symbols: |
 T+, N
|
| Risk Codes: | 45-46-60-61-21-25-26-34-42/43-48/23-50/53 |
| Safety: | 53-45-60-61 |
| Transport Information: | UN 3288 6.1/PG 2 |
| PSA: | 80.26000 |
| LogP: | -0.47520 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
- 90221-55-92-bromo-5-methylbenzaldehyde
- 885590-99-82,3-DIFLUORO-4-IODOBENZALDEHYDE
- 97730-31-9(S)-4'-(2-Methylbutyl)Biphenyl-4-Carbonitrile
What can I do for you?
Get Best Price
Consensus Reports
IARC Cancer Review: Group 1 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 49 , 1990,p. 49.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 23 , 1980,p. 205.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Human Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 49 , 1990,p. 49.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 23 , 1980,p. 205.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) . Reported in EPA TSCA Inventory. EPA Genetic Toxicology Program. Chromium and its compounds are on the Community Right-To-Know List.
Standards and Recommendations
OSHA PEL: Cl 0.1 mg(CrO3)/m3
ACGIH TLV: TWA 0.05 mg(CrO3)/m3
NIOSH REL: (Chromium(VI)) TWA 25 µg(Cr(VI))/m3; CL 50 µg/m3/15M
Analytical Methods
For occupational chemical analysis use NIOSH: Chromium Hexavalent 7024.
Specification
The Disodium chromate with CAS registry number of 7775-11-3 is also called Sodiumchromate. Its EINECS registry number is 231-889-5. The IUPAC name is disodium dioxido(dioxo)chromium. In addition, the molecular formula is CrH2O4.2Na and the molecular weight is 163.97. It is a kind of Yellow crystals or crystalline powder and belongs to the classes of Inorganics; Inorganic Salts; Salts; Sodium Salts; SodiumMetal and Ceramic Science; Synthetic Reagents.
Physical properties about this chemical are: (1)#H bond acceptors:4; (2)#H bond donors:2; (3)Polar Surface Area:74.6 ?2; (4)Exact Mass: 161.89971; (5)MonoIsotopic Mass: 161.89971; (6)Topological Polar Surface Area: 80.3; (7)Heavy Atom Count: 7; (8)Complexity: 62.2; (9)Covalently-Bonded Unit Count: 3.
Preparation of Disodium chromate: it can be prepared by chromite in the presence of strong oxidizing agents. The reaction temperature is 1100-1200 °C. The equation is as follows:
Uses of Disodium chromate: it is mainly used as corrosion inhibitors for ink, paint and metal, and used as oxidant in organic synthesis. In addition, it is a kind of inhibitor for concrete admixtures.
When you are using this chemical, please be cautious about it as the following:
It has risk of explosion by shock, friction, fire or other sources of ignition. And it contact with combustible material may cause fire. It may cause sensitization by inhalation and skin contact. Besides, it has danger of serious damage to health by prolonged exposure through inhalation. And it is very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. In addition, it may cause cancer and heritable genetic damage. You should avoid exposure - obtain special instruction before use. During using it, in case of accident or if you feel unwell, seek medical advice immediately (show label where possible). This material and/or its container must be disposed of as hazardous waste. Moreover, you should avoid release to the environment. You can refer to special instructions safety data sheet.
You can still convert the following datas into molecular structure:
(1)SMILES: [Na+].[Na+].[O-][Cr]([O-])(=O)=O
(2)InChI: InChI=1/Cr.2Na.4O/q;2*+1;;;2*-1/rCrO4.2Na/c2-1(3,4)5;;/q-2;2*+1
(3)InChIKey: PXLIDIMHPNPGMH-JYQPEEMKAO
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| cat | LD50 | intravenous | 164mg/kg (164mg/kg) | VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Agressologie. Revue Internationale de Physio-Biologie et de Pharmacologie Appliquees aux Effets de l'Agression. Vol. 8, Pg. 51, 1967. |
| dog | LDLo | intravenous | 235mg/kg (235mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
| guinea pig | LDLo | intradermal | 382mg/kg (382mg/kg) | PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Journal of Anatomy and Physiology. Vol. 11, Pg. 285, 1877. |
| guinea pig | LDLo | intraperitoneal | 206mg/kg (206mg/kg) | Archives of Environmental Health. Vol. 11, Pg. 201, 1965. | |
| guinea pig | LDLo | skin | 206mg/kg (206mg/kg) | Archives of Environmental Health. Vol. 11, Pg. 201, 1965. | |
| guinea pig | LDLo | subcutaneous | 30mg/kg (30mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
| mouse | LD50 | intraperitoneal | 32mg/kg (32mg/kg) | Comptes Rendus Hebdomadaires des Seances, Academie des Sciences. Vol. 257, Pg. 791, 1963. | |
| rabbit | LDLo | intradermal | 250mg/kg (250mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: MUSCLE WEAKNESS LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Journal of Anatomy and Physiology. Vol. 11, Pg. 285, 1877. |
| rabbit | LDLo | intravenous | 32mg/kg (32mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
| rabbit | LDLo | subcutaneous | 243mg/kg (243mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
| rat | LD50 | intraperitoneal | 57mg/kg (57mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: COMA | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 154, Pg. 243, 1965. |
| rat | LD50 | oral | 136mg/kg (136mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) CARDIAC: OTHER CHANGES SKIN AND APPENDAGES (SKIN): HAIR: OTHER | International Journal of Toxicology. Vol. 19, Pg. 338, 2000. |